235 related articles for article (PubMed ID: 19458355)
21. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
[TBL] [Abstract][Full Text] [Related]
22. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Evans GL; Morgan RA
Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
[TBL] [Abstract][Full Text] [Related]
23. Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.
Smith BM; Lyle MJ; Chen AC; Miao CH
J Thromb Haemost; 2020 Feb; 18(2):328-340. PubMed ID: 31609041
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
25. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
[TBL] [Abstract][Full Text] [Related]
26. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
[TBL] [Abstract][Full Text] [Related]
27. Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain.
Rawle FE; Pratt KP; Labelle A; Weiner HL; Hough C; Lillicrap D
J Thromb Haemost; 2006 Oct; 4(10):2172-9. PubMed ID: 16824190
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.
Miao CH
Expert Rev Hematol; 2010 Aug; 3(4):469-83. PubMed ID: 20976115
[TBL] [Abstract][Full Text] [Related]
29. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
30. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.
Su RJ; Epp A; Latchman Y; Bolgiano D; Pipe SW; Josephson NC
Mol Ther; 2010 Jan; 18(1):214-22. PubMed ID: 19755963
[TBL] [Abstract][Full Text] [Related]
31. In vivo induction of regulatory T cells for immune tolerance in hemophilia.
Wang X; Terhorst C; Herzog RW
Cell Immunol; 2016 Mar; 301():18-29. PubMed ID: 26454643
[TBL] [Abstract][Full Text] [Related]
32. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456
[TBL] [Abstract][Full Text] [Related]
33. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells.
Qadura M; Othman M; Waters B; Chegeni R; Walker K; Labelle A; Ozelo M; Hough C; Lillicrap D
J Thromb Haemost; 2008 Dec; 6(12):2095-104. PubMed ID: 18826393
[TBL] [Abstract][Full Text] [Related]
34. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.
Rossi G; Sarkar J; Scandella D
Blood; 2001 May; 97(9):2750-7. PubMed ID: 11313267
[TBL] [Abstract][Full Text] [Related]
35. Escape or Fight: Inhibitors in Hemophilia A.
Merlin S; Follenzi A
Front Immunol; 2020; 11():476. PubMed ID: 32265927
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
37. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
40. Regulatory T cells and their potential for tolerance induction in haemophilia A patients.
Schmidt A; Königs C;
Hamostaseologie; 2016 Nov; 36(Suppl. 2):S5-S12. PubMed ID: 27824212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
